NCT00210522View on ClinicalTrials.gov

An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy

PHASE2CompletedINTERVENTIONAL
Enrollment

421

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
EpilepsyEpilepsies, Partial
Interventions
DRUG

RWJ 333369

Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.

All Listed Sponsors
lead

SK Life Science, Inc.

INDUSTRY

NCT00210522 - An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy | Biotech Hunter | Biotech Hunter